ICON Public Company (ICLR) investor relations material

Executive summary

• Q4 and full-year 2025 results released with 2026 guidance and findings from an accounting investigation; Q4 2025 revenue reached $2,113m and full-year revenue was $8,251m, reflecting restatements due to prior revenue recognition issues.

• Investigation revealed improper revenue recognition adjustments from Q3 2023–Q4 2024, overstating revenue by $65.3m in 2023 and $92.7m in 2024; material weaknesses in internal controls identified and remediation plan underway.

• Commercial performance strong in Q4, with net bookings up 19% year-over-year, net business wins of $2,868m, and improved win rates, especially in biotech.

• Divestiture of Symphony Health completed, impacting full-year revenue by ~2%.

• Audit Committee investigation concluded; financials restated for 2023 and 2024 due to revenue overstatements.

Financial highlights

• Q4 2025 revenue: $2,113m, up 2.5% year-over-year and 1.3% sequentially; full-year 2025 revenue: $8,251m, up 0.8% over 2024.

• Adjusted EBITDA Q4: $327.1m (15.5% margin); full-year: $1,530.7m (18.6% margin), down 8.4% year-over-year.

• Adjusted EPS Q4: $2.52; full-year: $12.53.

• Q4 cash from operations: $234.2m; free cash flow: $862m; cash and equivalents at year-end: $647.3m.

• Net debt at year-end: $2.8b; leverage ratio: 1.8x net debt to adjusted EBITDA.

Outlook and guidance

• 2026 revenue guidance: $7,850m–$8,150m; adjusted EPS: $10.00–$11.00.

• EBITDA margin expected to improve to ~16.5% for 2026, with sequential margin progression through the year.

• Guidance excludes future share repurchases and M&A; capital expenditure planned at approximately $200m.

• Revenue headwinds expected from prior booking environment and Symphony Health divestiture; pass-through revenue projected flat year-over-year.

• Management anticipates sustainable growth into 2027 and beyond, supported by commercial momentum and strategic partnerships.